Back to Authors

Gao, Shan

https://orcid.org/0000-0003-3104-2425

A5103197996 | I1320553840

Mayo Clinic

Amgen (United States)

Citations 1

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

Blood Advances | October 21, 2019 | Volume: 3 | Issue: 20 | Pages: 3033-3037

10.1182/bloodadvances.2019000457 | PMID 31648325

Key Points MRD response has value as a prognostic factor for blinatumomab treatment in R/R B-cell precursor ALL. MRD response was associated with better outcomes in terms of OS and RFS in blinatumomab-treated R/R ALL.